Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MYHIBBIN.
GRISEOFULVIN, ULTRAMICROSIZE vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category D/X
Category C
Antifungal
Antifungal